子宫内膜异位症患者血浆及组织中骨桥蛋白表达及其作用机制的研究Expression of osteopontin in plasma and tissue in endometriosis and its mechanisms
靳卫国;李爱华;刘艳军;席焕英;张改英;陈双峰;任玉波;
摘要(Abstract):
目的:检测子宫内膜异位症(endometriosis,EM)组织中骨桥蛋白(osteopon-tin,OPN)、血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达,探讨子宫内膜异位症的发病机制,OPN在子宫内膜异位症血浆中的含量以及OPN在子宫内膜异位症诊断及鉴别诊断方面的应用。方法:用免疫组化SP法检测56例子宫内膜异位症患者异位内膜及在位内膜中OPN、VEGF的表达,用酶联免疫吸附方法检测患者术前血浆OPN含量。结果:(1)异位内膜OPN表达主要分布于腺上皮细胞细胞膜,阳性(+++++)表达率与在位内膜相似,明显高于对照内膜,差异有显著性(P<0.01),异位内膜细胞大多受挤压萎缩,缺乏典型的周期性改变;(2)VEGF在异位内膜胞浆染色,呈棕色颗粒,表达阳性,其中阳性(+++++)表达率与在位内膜相似,明显高于对照内膜,差异有显著性(P<0.01),异位内膜细胞大多受挤压萎缩,缺乏典型的周期性改变;(2)VEGF在异位内膜胞浆染色,呈棕色颗粒,表达阳性,其中阳性(+++++)表达率明显高于在位内膜及对照内膜(P<0.01);(3)异位内膜组织中OPN、VEGF表达有相关性(rs=0.596,P<0.01)。在子宫肌瘤对照内膜组织OPN、VEGF的表达则无相关性(rs=0.153,P=0.507);(4)子宫内膜异位症患者术前血浆OPN均值46.26±8.72ng/m l(15.54+++)表达率明显高于在位内膜及对照内膜(P<0.01);(3)异位内膜组织中OPN、VEGF表达有相关性(rs=0.596,P<0.01)。在子宫肌瘤对照内膜组织OPN、VEGF的表达则无相关性(rs=0.153,P=0.507);(4)子宫内膜异位症患者术前血浆OPN均值46.26±8.72ng/m l(15.54139.12ng/m l),高于良性肿瘤及正常对照组(P<0.01),后二者无显著差异。卵巢癌患者术前血浆OPN均值81.32±14.41ng/m l(22.72139.12ng/m l),高于良性肿瘤及正常对照组(P<0.01),后二者无显著差异。卵巢癌患者术前血浆OPN均值81.32±14.41ng/m l(22.72197.94ng/ml),较内异症患者水平高(P<0.01)。结论:OPN在异位内膜细胞高表达,可能推动异位内膜黏附和侵袭,OPN、VEGF可能通过促血管生成,共同促进异位内膜种植与生长,在子宫内膜异位症发生发展中起重要作用;OPN在盆腔包块鉴别诊断方面有一定应用价值。
关键词(KeyWords): 骨桥蛋白;血管内皮生长因子;子宫内膜异位症;免疫组织化学;酶联免疫吸附测定
基金项目(Foundation):
作者(Authors): 靳卫国;李爱华;刘艳军;席焕英;张改英;陈双峰;任玉波;
DOI: 10.13283/j.cnki.xdfckjz.2008.08.010
参考文献(References):
- [1]Kim JH,Skates SJ,Uede T,et al.Osteopontin as a poten-tial diagnostic biomarker for ovarian cancer[J].JAMA,2002,287:1671-1679
- [2]朱耀魁,屈洋,夏明翰,等.骨桥蛋白在子宫颈癌及子宫内膜癌组织的表达[J].中国病理生理杂志,2005,21:2414-2417
- [3]Matsuzaki S,Canis M,Darcha C,et al.Angiogenesis in en-dometriosis[J].Gynecol Obstet Invest,1998,46:111-115
- [4]Rittling SR,Chambers AF.Role of osteopontin in tumourprogression[J].Br J Cancer,2004,90:1877-1881
- [5]Johnson GA,Burghardt RC,Joyce MM,et al.Osteopontinis synthesized by uterine glands and a 45-kDa cleavagefragment is localized at the uterine-placental interfacethroughout ovine pregnancy[J].Biol Reprol,2003,69:92-98
- [6]von Wolff M,Strowitzki T,Becker V,et al.Endometrial os-teopontin,a ligand of beta3-integrin,is maximally ex-pressed around the time of the"implantation window"[J].Fertil Steril,2001,76:775-781
- [7]Wai PY,Kuo PC.The role of Osteopontin in tumor metas-tasis[J].J Surg Res,2004,121:228-241
- [8]陈辉,张忠福,方素云.子宫内膜异位症雌、孕激素受体的表达[J].辽宁医学杂志,2001,3:125-126
- [9]Bulun SE,Cheng YH,Yin P,et al.Progesterone resistancein endometriosis:link to failure to metabolize estradiol[J].Mol Cell Endocrinol,2006,248:94-103
- [10]朱耀魁,夏明翰,王晓玉,等.骨桥蛋白在子宫内膜异位症患者异位和在位内膜中的表达[J].中华妇产科杂志,2006,4l:343-344
- [11]Shijubo N,Uede T,Kon S,et al.Vascular endothelialgrowth factor and osteopontin in tumor biology[J].CritRev Oncog,2000,11:135-146
- [12]Senger DR,Ledbetter SR,Claffey KP,et al.Stimulationof endothelial cell migration by vascular permeabilityfactor/vascular endothelial growth factor through cooper-ative mechanisms involving the alphavbeta3 integrin,os-teopontin,and thrombin[J].Am J Pathol,1996,149:293-305
- [13]Tuck AB,Chambers AF.The role of osteopontin in breastcancer:clinical and experimental studies[J].J Mamma-ry Gland Biol Neoplasia,2001,6:419-429
- [14]Hirama M,Takahashi F,Takahashi K,et al.Osteopontinoverproduced by tumor cells acts as a potent angiogenicfactor contributing to tumor growth[J].Cancer Lett,2003,198:107-117
- [15]Pan HW,Ou YH,Peng SY,et al.Overexpression of os-teopontin is associated with intrahepatic metastasis,earlyrecurrence,and poorer prognosis of surgically resectedhepatocellular carcinoma[J].Cancer,2003,98:119-127
- [16]Singhal H,Bautista DS,Tonkin KS,et al.Elevated plas-ma osteopontin in metastatic breast cancer associatedwith increased tumor burden and decreased survival[J].Clin Cancer Res,1997,3:605-611
- [17]Nakae M,Iwamoto I,Fujino T,et al.Preoperative plasmaosteopontin level as a biomarker complementary to carbo-hydrate antigen 125 in predicting ovarian cancer[J].JObstet Gynaecol Res,2006,32:309-314
- [18]Schorge JO,Drake RD,Lee H,et al.Osteopontin as anadjunct to CA125 in detecting recurrent ovarian cancer[J].Clin Cancer Res,2004,10:3474-3478